Patent
Status of our key patents of core pipeline is as follows.
| Title of Invention | Oncolytic virus replicating selectively in tumor cells |
|---|---|
| Disease Area | Various types of cancers |
| Patent Owner | Oncolys BioPharma Inc. and Kansai TLO Co., Ltd. |
| Rights of Oncolys BioPharma | Owner of patents (*Note) |
| Country / Patent Number | Japan:3867968 USA:8163892 Europe:1553178 Australia:2003281310 Canada:2491907 China:ZL03816064.1 Hong Kong:1082958 Republic of Korea:10-0947194 New Zealand:537631 singapore:109.276 South Africa:2005/0047 |
| status | Patents concerning drug substance issued in 11 countries including Japan and the U.S.A. |
| Note: Japan patent is owned jointly by Oncolys BioPharma Inc. and Kansai TLO Co., Ltd. and patents issued in other than Japan solely owned by Oncolys BioPharma Inc. | |
| Title of Invention | Ainti-viral nucreoside analog and methods for treating viral infections, especially HIV infections |
|---|---|
| Disease Area | HIV |
| Patent Owner | Yale University, etc. |
| Rights of Oncolys BioPharma | Worldwide exclusive license |
| Country / Patent Number | Japan:4980059 USA:7589078, 8193165, 9126971 Europe:Pending Australia:2004260630 Canada:2514466 China:ZL200480010529.6 Hong Kong:1087341 Russian Federation:12844 Israel:169944 Republic of Korea:10-1228503 Mexico:281038 New Zealand:541594 Poland:219609 Singapore:115981 |
| Status | Patents concerning drug substance issued in 13 countries including Japan and the U.S.A. |
| Title of Invention | Novel depsipeptide compound |
|---|---|
| Disease Area | Various types of cancers |
| Patent Owner | Astellas Pharma Inc. |
| Rights of Oncolys BioPharma | Worldwide exclusive license |
| Country / Patent Number | Japan:3554707 USA:6670326, 7098024 Ireland:1142905 United Kingdom:1142905 Italy:1142905 Austria:1142905 Netherlands:1142905 Greece:1142905 Switzerland:1142905 Sweden:1142905 Spain:1142905 Denmark:1142905 Germany:60029084 Finland:1142905 France:1142905 Belgium:1142905 Portugal:1142905 Canada:2356845 China:ZL00802510.X Republic of Korea:10-0611265 |
| Status | Patents concerning drug substance issued in 20 countries including Japan, U.S.A., and Europe |
| Title of Invention | Telomelysin / GFP-expressing recombinant virus |
|---|---|
| Disease Area | Detection of cancer and inflammatory diseases |
| Patent Owner | Oncolys BioPharma Inc. |
| Rights of Oncolys BioPharma | Owner of Patents |
| Country / Patent Number | Japan:5006045 United Kingdom:2311499 France:2311499 Germany:2311499 Italy:2311499 Netherlands:2311499 Russian Federation:11880 India:246555 New Zealand:554799 Singapore:130465 |
| Status | Patents concerning substance issued in 10 countries including Japan and Europe and also protected by patents for OBP-301 (Telomelysin). |
| Title of Invention | Conditionally replication-competent adenovirus |
|---|---|
| Disease Area | Detection of cancer |
| Patent Owner | National Institute of Biomedical Innovation |
| Rights of Oncolys BioPharma | Worldwide exclusive license |
| Country / Patent Number | Japan:5812361, 5971599 USA:9624476 Europe:Pending China:103857795 Hong Kong:Pending Republic of Korea:Pending Australia:2012298013 Canada:Pending Russian:Pending India:Pending Singapore:11201400139 New Zealand:622585 |
| Status | Patents concerning substance issued in 6 countries including Japan and also protected by patents for OBP-301 (Telomelysin) and OBP-401 (TelomeScan) |
